Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atossa Therapeutics, Inc. - Common Stock (NQ: ATOS )

1.030 +0.030 (+3.00%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 408,821
Open 1.010
Bid (Size) 1.010 (25)
Ask (Size) 1.030 (66)
Prev. Close 1.000
Today's Range 1.010 - 1.030
52wk Range 0.7700 - 2.310
Shares Outstanding 125,785,200
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q2 2024
ATOS stock results show that Atossa Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
+10.16%
+10.16%
1 Month
-19.53%
-19.53%
3 Month
-26.43%
-26.43%
6 Month
N/A
N/A
1 Year
+22.18%
+22.18%

More News

Read More
3 Dirt-Cheap Drug Developers With Blockbuster Potential
Via InvestorPlace
3 Penny Stock Moonshots with 300%+ Upside Potential by 2025
Via InvestorPlace
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
Via InvestorPlace
MicroMarvel - Atossa Therapeutics
Via Talk Markets
Atossa Therapeutics backing Endoxifen in the fight against breast cancer
Via News Direct
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
Via InvestorPlace
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
Via InvestorPlace
ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Shhh! 3 Secret Penny Stocks Flying Below Wall Street’s Radar
Via InvestorPlace
ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
Via InvestorPlace
This Drug Developer Is Dedicated To "Transforming The Breast Cancer Paradigm"
Via Benzinga
Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
Via ACCESSWIRE
Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers – Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Breast Cancer-Focused Atossa Therapeutics Can Possibly Change Treatment Paradigm: Analyst
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
Via Benzinga
Could Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?
Via Benzinga
50% Of Women Have Elevated Breast Density, Which Significantly Decreases the Effectiveness of Mammography - Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis
Via ACCESSWIRE
50% Of Women Have Elevated Breast Density, Which Significantly Decreases The Effectiveness Of Mammography – Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis
Via Benzinga
3 Penny Stocks to Make Your ‘Get Rich’ Dreams Come True
Via InvestorPlace
3 Penny Stocks Set to Pass the $5 Mark Soon
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.